Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Bioengineered therapies for Kidney Disease
| Round | Raised | Date |
|---|---|---|
| Biz Plan Competition | $1M | 2023-06-12 |
| Seed | $125K | 2021-01-05 |
Total raised: $1M
Trestle Biotherapeutics develops bioengineered kidney tissue therapies built on stem cell and 3D bioprinting methods. It licensed kidney engineering technology from Harvard in 2022.
Source: Harvard OTD
Ben Shepherd and Alice Chen, both PhDs with backgrounds in stem cell biology and tissue engineering, lead Trestle. The company was founded in 2020.
Source: Harvard OTD
Trestle Biotherapeutics is based in San Diego, California.
Source: Harvard OTD
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. Trestle Biotherapeutics stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.